Although the anti-inflammatory properties of LRRK2 inhibitors are starting to be considered as disease-modifying treatment for PD, little is known about the beneficial effects of targeting LRRK2-related neuroinflammation in preclinical models. This evidence concerns the gene LRRK2 and Parkinson disease.